培美曲塞联合顺铂治疗非小细胞肺癌疗效及对患者细胞角质抗原21-1、磷酸化细胞外信号调节激酶水平的影响研究

Therapeutic effect of pemetrexed combined with cisplatin in treatment of non-small cell lung cancer and its influence on CYFRA21-1 and p-ERK levels

目的研究了培美曲塞联合顺铂对非小细胞癌的治疗效果及对患者细胞角质抗原21-1(CYFRA21-1)、磷酸化细胞外信号调节激酶(p-ERK)水平的影响。方法:纳入收治的非小细胞肺癌(NSCLC)患者94例,随机分为对照组和观察组,各47例。对照组使用多西他赛联合顺铂进行化疗,观察组使用培美曲塞联合顺铂进行治疗。比较两组的近期疗效、安全性和1年生存率,比较两组以及不同病理分型治疗前后的CYFRA21-1、糖类抗原125(CA125)、p-ERK水平。结果:对照组的治疗有效率明显低于观察组(P<0.05)。两组的1年生存率比较,差异无统计学意义(P>0.05)。治疗后,两组的CYFRA21-1、CA125、p-ERK水平均明显降低(P<0.05),其中对照组CYFRA21-1、CA125、p-ERK水平均明显高于观察组(P<0.05)。治疗后,NSCLC不同病理分型患者CYFRA21-1、CA125、p-ERK水平均明显下降(P<0.05),其中鳞癌患者CYFRA21-1、CA125、p-ERK水平均明显高于腺癌和鳞腺癌患者(P<0.05)。对照组恶心呕吐、肝功能损害和白细胞计数减少的发生率明显高于观察组(P<0.05)。结论:培美曲塞联合顺铂治疗NSCLC的疗效和安全性均较好,CYFRA21-1、CA125、p-ERK的水平经治疗后在不同病理分期患者中均明显下降,可作为评价NSCLC化疗效果的有效指标。

Objective:To study the therapeutic effect of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer(NSCLC)and its influence on CYFRA21-1 and p-ERK levels.Methods:94 NSCLC patients were randomly divided into control group and observation group,47 cases each.The control group was treated with docetaxel combined with cisplatin,and the observation group was treated with pemetrexed combined with cisplatin.The short-term efficacy,safety and 1-year survival rate of the two groups were compared,and the levels of CYFRA21-1,CA 125 and p-ERK in the two groups and different pathological types were compared before and after treatment.Results:The effective rate of treatment in the control group was significantly lower than that in the observation group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).After treatment,the levels of CYFRA21-1,CA 125 and p-ERK in the two groups were significantly reduced(P<0.05),and the levels of CYFRA21-1,CA 125 and p-ERK in the control group were significantly higher than those in the observation group(P<0.05).After treatment,the levels of CYFRA21-1,CA 125 and p-ERK in patients with different pathological types of NSCLC were decreased significantly(P<0.05),and the levels of CYFRA21-1,CA 125 and p-ERK in patients with squamous cell carcinoma were significantly higher than those in patients with adenocarcinoma and adeno-squamous carcinoma(P<0.05).The incidence of nausea and vomiting,liver function impairment and leukocyte count decrease in the control group was significantly higher than that in the observation group(P<0.05).Conclusion:Pemetrexed combined with cisplatin has good efficacy and safety in the treatment of NSCLC.The levels of CYFRA21-1,CA 125 and p-ERK after treatment are significantly reduced in patients with different pathological stages,which can be used as an effective index to evaluate the chemotherapy effect of NSCLC.